Tumour hypoxia represents a significant challenge to the curability of human tumours leading to treatment resistance and enhanced tumour regression. Tumour hypoxia can be detected by non-invasive techniques but the interrelationship between these techniques needs to be better defined. [ 18F]Fluoromisonidazole (18F-MISO) and Culabelled diacetyl-bis(N(4)-methylthiosemicarbazone (Cu-ATSM) PET, and blood oxygen level-dependent (BOLD) MRI are the lead contenders for human application based on their non-invasive nature, ease of use and robustness, measurement of hypoxia status, validity, ability to demonstrate heterogeneity and general availability; these techniques are the primary focus of this editorial. © 2005 International Cancer Imaging Society.
CITATION STYLE
Padhani, A. R. (2005). Where are we with imaging oxygenation in human tumours? Cancer Imaging. https://doi.org/10.1102/1470-7330.2005.0103
Mendeley helps you to discover research relevant for your work.